Aberrant expression of other CCT subunits, like CCT2, also correlated with Alzheimer’s disease or Parkinson’s disease and could be used as biomarkers to assist with neurological disease prognosis and management (Brehme et al., 2014; Xie H. et al., 2016; Liu et al., 2020). The gene discussed is CCT2; the disease is early-onset autosomal dominant Alzheimer disease.